home / stock / lgvn / lgvn news

LGVN News and Press, Longeveron Inc. From 07/20/23

Stock Information
Company Name: Longeveron Inc.
Stock Symbol: LGVN
Market: NASDAQ
Website: longeveron.com
Menu
LGVN LGVN Quote LGVN Short LGVN News LGVN Articles LGVN Message Board
Get LGVN Alerts

News, Short Squeeze, Breakout and More Instantly...
LGVN - Longeveron Appoints Lisa Locklear as Chief Financial Officer

MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as Executive Vice P...
LGVN - Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

MIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the...

LGVN - Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors

MIAMI, July 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science Officer ...

LGVN - HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

(NewsDirect) By David Willey, Benzinga Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. The Company, which is now conducting its phase 2a trial, is a clini...
LGVN - HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate - Could Longeveron's Lomecel-B Improve Outcomes?

--News Direct-- By David Willey, Benzinga Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. The Company, which is now conducting its phase 2a trial, is a cl...

LGVN - Longeveron Files Registration Statement for Rights Offering

MIAMI, June 27, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as Alzheimer’s Disease and Aging Frailty, announced today...

LGVN - Longeveron Welcomes Three New Prominent Board Members

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders MIAMI, June 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechno...
LGVN - Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript

2023-05-12 14:14:11 ET Longeveron Inc. (LGVN) Q1 2023 Earnings Conference Call May 12, 2023 08:30 AM ET Company Participants James Clavijo - Chief Financial Officer Wa'el Hashad - Chief Executive Officer Chris Min - Acting Chief Medical Officer & Consultant ...

LGVN - Longeveron GAAP EPS of -$0.22 misses by $0.01, revenue of $0.27M beats by $0.12M

2023-05-12 09:52:45 ET Longeveron press release ( NASDAQ: LGVN ): Q1 GAAP EPS of -$0.22 misses by $0.01 . Revenue of $0.27M (-27.0% Y/Y) beats by $0.12M . For further details see: Longeveron GAAP EPS of -$0.22 misses by $0.01, revenue of $0.27M beats by $...

LGVN - Longeveron GAAP EPS of -$0.22, revenue of $0.28M

2023-05-12 08:21:46 ET Longeveron press release ( NASDAQ: LGVN ): Q1 GAAP EPS of -$0.22. Revenue of $0.28M (-24.3% Y/Y). For further details see: Longeveron GAAP EPS of -$0.22, revenue of $0.28M
Previous 10 Next 10